UK digital-care study reports six-month weight loss in women; no comparator limits conclusions

An October 16 Nature Medicine paper reports a real-world observational study of a UK digital weight-management program in 8,127 adult women, defined by the study as female sex at birth. Almost all participants received tirzepatide, with a small number receiving semaglutide. These are six-month service outcomes, not a randomized trial comparing digital care with a clinic, another program or no treatment.

The women were recruited between November 2024 and January 2025 and began treatment by February 2025. The program combined remote eligibility checks, clinician review, biochemical testing and ongoing digital monitoring. Participants paid for care, and the provider partly subsidized the program during the study. Mean baseline body mass index was 38.2, and 88.0% of participants were white, limiting how broadly the findings can be applied.

Among the 7,297 participants with paired six-month weight measurements, mean weight reduction was 16.1 kilograms, or 15.5% of baseline weight. In that measured group, 83.1% lost at least 10% and 22.4% lost at least 20%. Those percentages are not results for all 8,127 people who started treatment. Complete-case analysis and missing follow-up data leave room for selection bias even though the authors performed sensitivity analyses.

The paper reports that 7,429 participants, or 91.4%, remained on treatment at six months. Paired blood-test data showed changes in glucose and lipid markers, but denominators differed by test. These short-term measurements do not establish prevention of heart attacks, long-term diabetes remission or sustained results after medication stops. There was no untreated or in-person-care comparison that could isolate the effect of the digital program.

At least one side effect was reported by 5,092 participants, or 62.7%. Of those reporting side effects, 7.7% described their maximum severity as severe. The authors identified no serious treatment-related adverse events, but six months of observational reporting cannot establish the absence of rare or longer-term harms. Self-reported medical history and other medication use were not systematically verified against health records.

The paper discloses that two authors worked for the companies co-operating the program and that some authors received related consulting fees; it also identifies research funding administered through University College London. The self-pay population, partial subsidy, missing data and lack of a comparator should accompany the reported outcomes. This study does not verify any Houston provider, endorse a prescribing service or support unsupervised use. No dosing, injection or buying instructions are provided.